Insys Therapeutics (INSY) Shares Up 0.7%
Insys Therapeutics Inc (NASDAQ:INSY) shares shot up 0.7% on Monday . The company traded as high as $4.44 and last traded at $4.44. 44,984 shares were traded during trading, a decline of 96% from the average session volume of 1,176,441 shares. The stock had previously closed at $4.41.
A number of research firms have recently weighed in on INSY. Zacks Investment Research raised shares of Insys Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 4th. ValuEngine cut shares of Insys Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 13th. Cantor Fitzgerald assumed coverage on shares of Insys Therapeutics in a research note on Tuesday, January 22nd. They set an “overweight” rating and a $4.40 price target on the stock. Finally, Janney Montgomery Scott restated a “buy” rating and set a $11.00 price target on shares of Insys Therapeutics in a research note on Wednesday, December 19th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. Insys Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $7.68.
The company has a market cap of $326.79 million, a P/E ratio of -8.86 and a beta of 2.30.
COPYRIGHT VIOLATION WARNING: “Insys Therapeutics (INSY) Shares Up 0.7%” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://theolympiareport.com/2019/02/11/insys-therapeutics-insy-shares-up-0-7.html.
About Insys Therapeutics (NASDAQ:INSY)
Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
Read More: Is a Roth IRA right for you?
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.